The WACC of Britannia Life Sciences Inc (BLAB.CN) is 9.1%.
| Range | Selected | |
| Cost of equity | 5.20% - 5.90% | 5.55% |
| Tax rate | 0.20% - 0.80% | 0.50% |
| Cost of debt | 5.40% - 23.20% | 14.30% |
| WACC | 5.3% - 12.9% | 9.1% |
| Category | Low | High |
| Long-term bond rate | 3.2% | 3.7% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | -0.28 | -0.28 |
| Additional risk adjustments | 3.5% | 4.0% |
| Cost of equity | 5.20% | 5.90% |
| Tax rate | 0.20% | 0.80% |
| Debt/Equity ratio | 0.69 | 0.69 |
| Cost of debt | 5.40% | 23.20% |
| After-tax WACC | 5.3% | 12.9% |
| Selected WACC | 9.1% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for BLAB.CN:
cost_of_equity (5.55%) = risk_free_rate (3.45%) + equity_risk_premium (5.60%) * adjusted_beta (-0.28) + risk_adjustments (3.75%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.